Basking Biosciences, Inc. Email Format

Biotechnology ResearchNorth Carolina, United States11-50 Employees

Basking Biosciences, Inc. is a clinical-stage biotechnology company based in North Carolina, focused on developing treatments for potentially life-threatening blood clots. Its lead program, BB-031, is being developed as a rapid-onset, short-acting thrombolytic therapy with a reversal agent for acute ischemic stroke, aiming to improve safety and enable timely treatment for more patients. The product works by inhibiting von Willebrand Factor, a key driver of clot formation, to deliver targeted thrombolytic activity.

The company operates within the biotechnology research space, developing therapies intended for patients experiencing acute thrombosis and seeking to expand access to care for stroke. A notable recent development is the appointment of Julia Owens as chief executive officer in 2025. This leadership change accompanies ongoing clinical development of BB-031 as the company advances its investigational approaches.

Get verified Basking Biosciences, Inc. emails free

Company overview Employee directory